PRKAA2 and Alzheimer disease: Given that aberrant AMPK activation due to energy deficiency has been reported in degenerating neurons of several neurodegenerative diseases (including Alzheimer’s disease AD; Chen et al., 2009; Mairet-Coello et al., 2013; Ma et al., 2014; Chang et al., 2021), Huntington’s disease (HD; Ju et al., 2011, 2014), and amyotrophic lateral sclerosis (ALS; Lim et al., 2012; Liu et al., 2015a,b), a better understanding of the function and regulation of AMPK during neurodegeneration may provide potential targets for the development of new treatments for neurodegeneration diseases.